Akoya Biosciences (AKYA) Company Overview

CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced today that Argonaut will act as the manufacturing partner for Akoya's IVD assays currently in development. This agreement builds on years of collaboration between Argonaut and Akoya, reflecting Argonaut's prove.

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust

MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience.

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.51 per share a year ago.

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Akoya Biosciences, Inc. (NASDAQ: AKYA) Q1 2024 Earnings Conference Call on May 13, 2024 at 5:00 PM ET with Company Participants Priyam Shah, Brian McKelligon, and Johnny Ek, as well as various Conference Call Participants. Thank you for joining the Akoya Biosciences First Quarter 2024 Earnings Conference Call.

Akoya Biosciences (AKYA) reported a quarterly loss of $0.35 per share, which was higher than the expected loss of $0.30 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.49 per share reported in the same quarter last year.